Treasury director Rodrigo Robledo says investor relations work has paid off

◆ Two steps to terms debated ◆ Priced flat to fair value or even with negative concession ◆ Investors split on long-dated holdco supply

◆ Norwegian bank increases size ◆ Issuer meets spread objective ◆ Banker said he drew confidence from secondaries

◆ Issuers opt for extra guidance as market softens ◆ Enexis takes size at six years ◆ DSM-Firmenich lands tight

◆ Madrid plans 10 year deal ◆ Bpifrance set to launch EuGB ◆ MuniFin 'rare and well regarded'

This week's flurry of deals takes year to date volume beyond £8bn

Shipbuilder's shares fall 10% after capital raise

◆ Energy pair bring three tranches ◆ Sub-100bp senior/hybrid spreads secured ◆ Single digit concessions offered

Founder of climate investing think tank wants to apply ideas as bond investor

When loans' LTVs hit 80%, Bitcoin stakes are liquidated in seconds

London continues to benefit from metal price volatility

Latest issue rides on coattails of big tech investment spree

Ivory Coast squeezed tight, taking $1.3bn in an 'aggressive' execution

Blackstone is targeting a quicker than usual three day execution

The country is one of the highest regarded sovereign issuers on the continent

The government has been much more proactive in its debt management since a scare in 2024

The yield was ultra high but Congo had little room to manoeuvre

Benin showed Islamic issuance is a viable market for sub-Saharan African sovereigns

When the stakes are high, a small change in odds merits a big reaction

No one wins playing the blame game

Craig Coben examines whether it is true that no good deed goes unpunished

Anis Lahlou is chief investment officer at Aperture Investors in London. He believes that asset managers must change the way they charge fees to their investors, by only charging them for market-beating performance.

BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.

The International Finance Facility for Immunisation (IFFIm) was set up in 2006 to provide funding to Gavi, the Vaccine Alliance, itself a public/private sector partnership, to expedite the vaccination of children in the poorest countries against endemic infectious diseases. Doris Herrera-Pol, IFFIm board member and former director of global capital markets at the World Bank, spoke to GlobalCapital about the role the capital markets can play in the development and deployment of a Covid-19 vaccine.